Cargando…

The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology

Canada has among the highest incidence and prevalence of inflammatory bowel disease (IBD) in the world. After decades of rising incidence of IBD in Canada during the 20th Century, the prevalence of IBD in 2018 is 0.7% of the Canadian population. Forecasting models predict that prevalence of IBD will...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, Gilaad G, Bernstein, Charles N, Coward, Stephanie, Bitton, Alain, Murthy, Sanjay K, Nguyen, Geoffrey C, Lee, Kate, Cooke-Lauder, Jane, Benchimol, Eric I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512243/
https://www.ncbi.nlm.nih.gov/pubmed/31294381
http://dx.doi.org/10.1093/jcag/gwy054
_version_ 1783417675003723776
author Kaplan, Gilaad G
Bernstein, Charles N
Coward, Stephanie
Bitton, Alain
Murthy, Sanjay K
Nguyen, Geoffrey C
Lee, Kate
Cooke-Lauder, Jane
Benchimol, Eric I
author_facet Kaplan, Gilaad G
Bernstein, Charles N
Coward, Stephanie
Bitton, Alain
Murthy, Sanjay K
Nguyen, Geoffrey C
Lee, Kate
Cooke-Lauder, Jane
Benchimol, Eric I
author_sort Kaplan, Gilaad G
collection PubMed
description Canada has among the highest incidence and prevalence of inflammatory bowel disease (IBD) in the world. After decades of rising incidence of IBD in Canada during the 20th Century, the prevalence of IBD in 2018 is 0.7% of the Canadian population. Forecasting models predict that prevalence of IBD will continue to rise to 1.0% of the population by 2030. In 2018, the number of Canadians living with IBD is approximately 270,000 and is predicted to rise to 403,000 Canadians in 2030. Inflammatory bowel disease affects all age groups with adolescents and young adults at highest risk of diagnosis. Canadians of all ethnicities are being diagnosed with IBD including known high-risk groups such as Ashkenazi Jews and offspring of South Asian immigrants who were previously thought to be low risk. Moreover, IBD has evolved into a global disease with rising incidence in newly industrialized countries in Asia and South America. The causes of IBD remain unsolved; however, the high rates of disease in Western countries and its emergence in newly industrialized countries suggest that environmental factors associated with urbanization, modernization, or Western diets may be pertinent to understanding the pathogenesis of the disease. HIGHLIGHTS: 1. Canada continues to have among the highest prevalence of IBD in the world. 2. Today, approximately 270,000 Canadians live with IBD. By 2030 it is estimated that nearly 403,000 Canadians will have a diagnosis of IBD. 3. Inflammatory bowel disease has become a worldwide disease with increasing rates in Asia, Africa, and South America—continents where IBD was rarely diagnosed prior to 1990. 4. The causes of IBD are unknown, but the high rates of disease over the past 60 years in Western countries and the emergence of disease in developing countries suggest that factors associated with urbanization, modernization, or Western diets may be pertinent to understanding the pathogenesis of the disease. 5. Many of the leading hypotheses as to the causes of IBD tie in with alteration of the gut microbiome, the suite of organisms that reside in the bowel and maintain bowel health throughout life. KEY SUMMARY POINTS: 1. The incidence (the number of new diagnoses annually) of IBD rose throughout the 20th century in Canada and then stabilized at the turn of the 21st century. 2. The prevalence (the total number of diagnosed persons in the population) of IBD in Canada is among the highest in the world. 3. Today, 270,000 (0.7%, or 7 in 1000) Canadians are estimated to live with IBD. By 2030, that number is expected to rise to 403,000 Canadians (1% or 1 in 100). 4. Inflammatory bowel disease can be diagnosed at any age. However, the age groups that are most likely to be diagnosed are adolescents and young adults from 20 to 30 years of age. 5. Inflammatory bowel disease in Canada affects the lives of Canadians of all ethnicities, including known high-risk groups such as Ashkenazi Jews, and those thought previously to be at low risk, such as first-generation offspring of South Asian immigrants. 6. Canadian health policy makers will need to prepare the Canadian health care system for the rising burden of IBD. 7. As newly industrialized countries in Asia, Africa, and South America are transitioning to a Westernized society, IBD has emerged and its incidence in these countries is rising rapidly. 8. The gut microbiome includes microorganisms that maintain digestive health. Thus, changes in the microbiome, which may change the immune system’s response to triggers, may be important in initiating and perpetuating IBD. 9. A number of factors can alter the gut microbiome and early childhood may be a particularly important time such that breastfeeding, early life diet, use of antibiotics, infections, and other environmental exposures may impact the gut microbiome in such a way that facilitates developing IBD. 10. Smoking is associated with an increased risk and worsening disease course of Crohn’s disease. Quitting smoking is associated with an increased risk of developing ulcerative colitis. Therefore, never initiating smoking can mitigate the risk for IBD. Educational programs aimed at those at-risk for IBD should emphasize the risk of starting to smoke tobacco. 11. Modifying exposure to environmental risk factors associated with the Westernization of society (e.g., Western diet and lifestyles) may provide an avenue for reducing the risk of IBD in Canada and worldwide. GAPS IN KNOWLEDGE AND FUTURE DIRECTIONS: 1. While the incidence of IBD appears to be stabilizing in some regions in Canada, IBD may be occurring more frequently in certain populations such as in children, South Asians, Ashkenazi Jews, and immigrants. Future research should focus on the changing demographics of IBD in Canada. 2. The prevalence of IBD will rise steadily over the next decade. To enable better health care system planning and to respond adequately to the increasing burden of IBD, ongoing surveillance of the epidemiology and health services utilization of IBD in Canada is necessary. 3. Most studies have focused on the mortality associated with IBD. Future research is necessary to assess health-adjusted life expectancy and overall life expectancy for those living with IBD. 4. Analyses of resources, infrastructure, and personnel need to be modeled into the future in order to prepare our health care system for the rising burden of IBD. 5. Research on the interaction between genes, microbes, and our environment will inform our understanding of the pathogenesis of IBD, information necessary to prevent IBD in the future.
format Online
Article
Text
id pubmed-6512243
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-65122432019-07-10 The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology Kaplan, Gilaad G Bernstein, Charles N Coward, Stephanie Bitton, Alain Murthy, Sanjay K Nguyen, Geoffrey C Lee, Kate Cooke-Lauder, Jane Benchimol, Eric I J Can Assoc Gastroenterol Supplement Articles Canada has among the highest incidence and prevalence of inflammatory bowel disease (IBD) in the world. After decades of rising incidence of IBD in Canada during the 20th Century, the prevalence of IBD in 2018 is 0.7% of the Canadian population. Forecasting models predict that prevalence of IBD will continue to rise to 1.0% of the population by 2030. In 2018, the number of Canadians living with IBD is approximately 270,000 and is predicted to rise to 403,000 Canadians in 2030. Inflammatory bowel disease affects all age groups with adolescents and young adults at highest risk of diagnosis. Canadians of all ethnicities are being diagnosed with IBD including known high-risk groups such as Ashkenazi Jews and offspring of South Asian immigrants who were previously thought to be low risk. Moreover, IBD has evolved into a global disease with rising incidence in newly industrialized countries in Asia and South America. The causes of IBD remain unsolved; however, the high rates of disease in Western countries and its emergence in newly industrialized countries suggest that environmental factors associated with urbanization, modernization, or Western diets may be pertinent to understanding the pathogenesis of the disease. HIGHLIGHTS: 1. Canada continues to have among the highest prevalence of IBD in the world. 2. Today, approximately 270,000 Canadians live with IBD. By 2030 it is estimated that nearly 403,000 Canadians will have a diagnosis of IBD. 3. Inflammatory bowel disease has become a worldwide disease with increasing rates in Asia, Africa, and South America—continents where IBD was rarely diagnosed prior to 1990. 4. The causes of IBD are unknown, but the high rates of disease over the past 60 years in Western countries and the emergence of disease in developing countries suggest that factors associated with urbanization, modernization, or Western diets may be pertinent to understanding the pathogenesis of the disease. 5. Many of the leading hypotheses as to the causes of IBD tie in with alteration of the gut microbiome, the suite of organisms that reside in the bowel and maintain bowel health throughout life. KEY SUMMARY POINTS: 1. The incidence (the number of new diagnoses annually) of IBD rose throughout the 20th century in Canada and then stabilized at the turn of the 21st century. 2. The prevalence (the total number of diagnosed persons in the population) of IBD in Canada is among the highest in the world. 3. Today, 270,000 (0.7%, or 7 in 1000) Canadians are estimated to live with IBD. By 2030, that number is expected to rise to 403,000 Canadians (1% or 1 in 100). 4. Inflammatory bowel disease can be diagnosed at any age. However, the age groups that are most likely to be diagnosed are adolescents and young adults from 20 to 30 years of age. 5. Inflammatory bowel disease in Canada affects the lives of Canadians of all ethnicities, including known high-risk groups such as Ashkenazi Jews, and those thought previously to be at low risk, such as first-generation offspring of South Asian immigrants. 6. Canadian health policy makers will need to prepare the Canadian health care system for the rising burden of IBD. 7. As newly industrialized countries in Asia, Africa, and South America are transitioning to a Westernized society, IBD has emerged and its incidence in these countries is rising rapidly. 8. The gut microbiome includes microorganisms that maintain digestive health. Thus, changes in the microbiome, which may change the immune system’s response to triggers, may be important in initiating and perpetuating IBD. 9. A number of factors can alter the gut microbiome and early childhood may be a particularly important time such that breastfeeding, early life diet, use of antibiotics, infections, and other environmental exposures may impact the gut microbiome in such a way that facilitates developing IBD. 10. Smoking is associated with an increased risk and worsening disease course of Crohn’s disease. Quitting smoking is associated with an increased risk of developing ulcerative colitis. Therefore, never initiating smoking can mitigate the risk for IBD. Educational programs aimed at those at-risk for IBD should emphasize the risk of starting to smoke tobacco. 11. Modifying exposure to environmental risk factors associated with the Westernization of society (e.g., Western diet and lifestyles) may provide an avenue for reducing the risk of IBD in Canada and worldwide. GAPS IN KNOWLEDGE AND FUTURE DIRECTIONS: 1. While the incidence of IBD appears to be stabilizing in some regions in Canada, IBD may be occurring more frequently in certain populations such as in children, South Asians, Ashkenazi Jews, and immigrants. Future research should focus on the changing demographics of IBD in Canada. 2. The prevalence of IBD will rise steadily over the next decade. To enable better health care system planning and to respond adequately to the increasing burden of IBD, ongoing surveillance of the epidemiology and health services utilization of IBD in Canada is necessary. 3. Most studies have focused on the mortality associated with IBD. Future research is necessary to assess health-adjusted life expectancy and overall life expectancy for those living with IBD. 4. Analyses of resources, infrastructure, and personnel need to be modeled into the future in order to prepare our health care system for the rising burden of IBD. 5. Research on the interaction between genes, microbes, and our environment will inform our understanding of the pathogenesis of IBD, information necessary to prevent IBD in the future. Oxford University Press 2019-02 2018-11-02 /pmc/articles/PMC6512243/ /pubmed/31294381 http://dx.doi.org/10.1093/jcag/gwy054 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Articles
Kaplan, Gilaad G
Bernstein, Charles N
Coward, Stephanie
Bitton, Alain
Murthy, Sanjay K
Nguyen, Geoffrey C
Lee, Kate
Cooke-Lauder, Jane
Benchimol, Eric I
The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology
title The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology
title_full The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology
title_fullStr The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology
title_full_unstemmed The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology
title_short The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology
title_sort impact of inflammatory bowel disease in canada 2018: epidemiology
topic Supplement Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512243/
https://www.ncbi.nlm.nih.gov/pubmed/31294381
http://dx.doi.org/10.1093/jcag/gwy054
work_keys_str_mv AT kaplangilaadg theimpactofinflammatoryboweldiseaseincanada2018epidemiology
AT bernsteincharlesn theimpactofinflammatoryboweldiseaseincanada2018epidemiology
AT cowardstephanie theimpactofinflammatoryboweldiseaseincanada2018epidemiology
AT bittonalain theimpactofinflammatoryboweldiseaseincanada2018epidemiology
AT murthysanjayk theimpactofinflammatoryboweldiseaseincanada2018epidemiology
AT nguyengeoffreyc theimpactofinflammatoryboweldiseaseincanada2018epidemiology
AT leekate theimpactofinflammatoryboweldiseaseincanada2018epidemiology
AT cookelauderjane theimpactofinflammatoryboweldiseaseincanada2018epidemiology
AT benchimolerici theimpactofinflammatoryboweldiseaseincanada2018epidemiology
AT kaplangilaadg impactofinflammatoryboweldiseaseincanada2018epidemiology
AT bernsteincharlesn impactofinflammatoryboweldiseaseincanada2018epidemiology
AT cowardstephanie impactofinflammatoryboweldiseaseincanada2018epidemiology
AT bittonalain impactofinflammatoryboweldiseaseincanada2018epidemiology
AT murthysanjayk impactofinflammatoryboweldiseaseincanada2018epidemiology
AT nguyengeoffreyc impactofinflammatoryboweldiseaseincanada2018epidemiology
AT leekate impactofinflammatoryboweldiseaseincanada2018epidemiology
AT cookelauderjane impactofinflammatoryboweldiseaseincanada2018epidemiology
AT benchimolerici impactofinflammatoryboweldiseaseincanada2018epidemiology